Sofpironium bromide is a Small Molecule owned by Botanix Pharmaceuticals, and is involved in 16 clinical trials, of which 14 were completed, and 2 are ongoing.
Sofpironium bromide acts by antagonizing the M3 receptors which are involved in the phenomina of sweating. The sweat glands are innervated sympathetically by postganglionic fibers but the released peripheral transmitter is acetylcholine that binds to postsynaptically localized M3 muscarinic receptors of the eccrine glands and triggers sweat production. BBI-4000 prevents the excessive sweat production associated with hyperhydrosis by preventing the binding of acetylcholine to M3 receptors of the eccrine glands.
The revenue for Sofpironium bromide is expected to reach a total of $342m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Sofpironium bromide NPV Report.
Sofpironium bromide was originated by Bodor Laboratories and is currently owned by Botanix Pharmaceuticals. Kaken Pharmaceutical is the other company associated in development or marketing of Sofpironium bromide.
Sofpironium bromide Overview
Sofpironium bromide (Ecclock) is an anticholinergic agent. It is formulates as gel for topical application. Ecclock is indicated for the treatment of primary axillary hyperhidrosis.
Sofpironium bromide (BBI-4000) is under development for the treatment of primary palmoplantar hyperhidrosis, primary focal hyperhidrosis and chronic obstructive pulmonary disease (COPD). It is administered topically. BBI-4000 is a new molecular entity (NME) targeting muscarinic receptor-3.
Kaken Pharmaceutical Overview
Kaken Pharmaceutical (Kaken) is a specialty pharmaceutical company that conducts research and development of drugs, agrochemicals and medical equipments. The company offers solutions in the fields of orthopedics, dermatology, immunology, inflammation, allergies, fungal infections and pain relief. Kaken also offers fungicides, rice herbicide, anti-coccidial for chickens and polypeptide antibiotics. The company conducts research in inflammation and immunology, neurological pain relief and fungal infection areas. It markets products through license and distribution agreements with companies in the US, Canada, Taiwan, China, South Korea, Israel and Jordan and operates sales offices in various places in Japan. Kaken is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY76,034 million for the fiscal year ended March 2022 (FY2022), an increase of 1.4% over FY2021. In FY2022, the company’s operating margin was 17.4%, compared to an operating margin of 23.6% in FY2021. In FY2022, the company recorded a net margin of 12.6%, compared to a net margin of 17.9% in FY2021. The company reported revenues of JPY18,622 million for the second quarter ended September 2022, an increase of 2.3% over the previous quarter.
Quick View – Sofpironium bromide
|Highest Development Stage|